房颤的药物治疗进展
摘要
房颤目前的治疗手段主要是药物治疗和导管消融手术。使用药物治疗的方法包括节律控制和控制心室率,同时需要与抗凝治疗联合应用。药物治疗效果确切且经济,病人可接受度较好。本文对房颤的药物治疗进展展开综述,分析各类药物的在房颤治疗中的应用。
引文
[1]周自强,胡大一,陈捷, et al.中国心房颤动现状的流行病学研究[J].中华内科杂志, 2004, 43(7):491-494.
[2] Wyse D G, Waldo A L, Dimarco J P, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation.[J]. N Engl J Med, 2002, 347(23):1834-1840.
[3] Camm A J, Capucci A, Hohnloser S H, et al. A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation[J].Journal of the American College of Cardiology, 2011, 57(3):313-321.
[4] Scirica B M, Belardinelli L, Chaitman B R, et al. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial.[J]. Europace, 2015, 17(1):32-37.
[5] Verrier R L, Silva A F, Bonatti R, et al. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.[J]. Journal of Cardiovascular Electrophysiology, 2015,26(3):329-335.
[6] Pugliano M, Costantino G, Podda G M. Dronedarone in atrial fibrillation[J]. New England Journal of Medicine, 2009, 360(23):2480-1.
[7] Joghetaei N N, Weirich G G, Huber W W, et al. Acute liver failure associated with dronedarone.[J]. Circ Arrhythm Electrophysiol,2011, 4(4):592-593.
[8] Healey J S, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation:a cohort study[J]. Lancet, 2016, 388(10050):1161-1169.
[9] Camm A J, Amarenco P, Haas S, et al. XANTUS:a real-world,prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.[J]. European Heart Journal, 2016, 37(14):1145-1153.
[10] Yao H, Jiang L, Lin X, et al. Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation[J]. Biomedicine&Pharmacotherapy, 2016, 83:687-692.
[11] Hsieh Y C, Hung C Y, Li C H, et al. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation:A Nationwide Cohort Study[J]. Medicine, 2016,95(20):e3721.
[2] Wyse D G, Waldo A L, Dimarco J P, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation.[J]. N Engl J Med, 2002, 347(23):1834-1840.
[3] Camm A J, Capucci A, Hohnloser S H, et al. A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation[J].Journal of the American College of Cardiology, 2011, 57(3):313-321.
[4] Scirica B M, Belardinelli L, Chaitman B R, et al. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial.[J]. Europace, 2015, 17(1):32-37.
[5] Verrier R L, Silva A F, Bonatti R, et al. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.[J]. Journal of Cardiovascular Electrophysiology, 2015,26(3):329-335.
[6] Pugliano M, Costantino G, Podda G M. Dronedarone in atrial fibrillation[J]. New England Journal of Medicine, 2009, 360(23):2480-1.
[7] Joghetaei N N, Weirich G G, Huber W W, et al. Acute liver failure associated with dronedarone.[J]. Circ Arrhythm Electrophysiol,2011, 4(4):592-593.
[8] Healey J S, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation:a cohort study[J]. Lancet, 2016, 388(10050):1161-1169.
[9] Camm A J, Amarenco P, Haas S, et al. XANTUS:a real-world,prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.[J]. European Heart Journal, 2016, 37(14):1145-1153.
[10] Yao H, Jiang L, Lin X, et al. Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation[J]. Biomedicine&Pharmacotherapy, 2016, 83:687-692.
[11] Hsieh Y C, Hung C Y, Li C H, et al. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation:A Nationwide Cohort Study[J]. Medicine, 2016,95(20):e3721.